LTGO Financials

Income Statement
MetricQ3 2026
Revenue
0
Cost of Revenue
0
Gross Profit
0
Operating Expenses
22.9M
R&D
17.5M
SG&A
5.4M
Operating Income
-22929000
EBITDA
-22876000
Net Income
-20949000
EPS (Basic)
$-0.55
EPS (Diluted)
$-0.55
Shares (Diluted)
37.8M
Latigo Biotherapeutics (LTGO) — Financials